A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: A report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

Gastric Cancer

Volumn 14, Issue 3, 2011, Pages 226-233

  Hamaguchi, Tetsuya ^a   Shirao, Kuniaki ^a,b   Ohtsu, Atsushi ^c   Hyodo, Ichinosuke ^d   Arai, Yasuaki ^e   Takiuchi, Hiroya ^f   Fujii, Hirofumi ^g   Yoshida, Motoki ^f,h   Saito, Hiroshi ⁱ   Denda, Tadamichi ^j   Koizumi, Wasaburo ^k   Iwase, Hiroaki ^l   Boku, Narikazu ^m  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^g TOCHIGI CANCER CENTER   (Japan)

^h KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

ⁱ Yamagata Prefectural Central Hospital   (Japan)

^j CHIBA CANCER CENTER   (Japan)

^k KITASATO UNIVERSITY HOSPITAL   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^m SHIZUOKA CANCER CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN; IRINOTECAN; METHOTREXATE; MITOMYCIN C; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; JAPAN; LEUKOPENIA; LOW DRUG DOSE; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 85027924308     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0030-8     Document Type: Article

References (45)

1. Statistics of Cancer, Center for Information Services, National Cancer Center, Japan. http://ganjoho.ncc.go.jp/public/statistics/pub/update.html.
2. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5:189-90. (Pubitemid 24062577)
3. Murad A, Santiago F, Petroianou A. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41. (Pubitemid 23182046)
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71: 587-91.
5. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
6. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.
7. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27: abstr 4540.
8. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1994;21:1033-8. (Pubitemid 24225031)
9. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999;17:319-23. (Pubitemid 29022409)
10. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-6. (Pubitemid 34132291)
11. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270-5. (Pubitemid 29470662)
12. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004;15:1773-81. (Pubitemid 40017161)
13. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450-7.
14. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50:604-10.
15. Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, et al. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol. 2001;12:1729-35. (Pubitemid 34105663)
16. Yamada Y, Shirao K, Hyodo I, Arai Y, Denda T, Ambo T, et al. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol. 2003; 52:125-30. (Pubitemid 37041345)
17. Green S, Benedetti J, Crowley J. Clinical trials in oncology (interdisciplinary statistics). 2nd ed. Boca Raton: Chapman & Hall/CRC; 2002.
18. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9:307-10. (Pubitemid 28241819)
19. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluoro-uracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003; 21:54-9.
20. Schmitz SH, Voliotis DL, Schimke J, Diehl V. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology. 1994;51:502-6. (Pubitemid 24347031)
21. Vanhoefer U, Wilke H, Weh HJ, Clemens M, Harstrick A, Stahl M, et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol. 1994;5:850-1. (Pubitemid 24341880)
22. Hartmann JT, Kanz L, Bokemeyer C. Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma. Anticancer Res. 2000;20:1177-82. (Pubitemid 30240697)
23. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 2002;16:16-8.
24. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003;14:383-7. (Pubitemid 36367414)
25. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004;34:8-13. (Pubitemid 43118052)
26. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol. 2004;27:477-80. (Pubitemid 39371942)
27. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, et al. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol. 2005;28:581-5. (Pubitemid 41790010)
28. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leuco-vorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer. 2005;92:1850-4. (Pubitemid 40826132)
29. Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res. 2005;25:2973-7.
30. Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, et al. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs. 2005;16:621-5. (Pubitemid 40867293)
31. Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, Andre T, et al. Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer. 2006;93:E1-6.
32. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer. 2007;10:104-11. (Pubitemid 46955936)
33. Hartmann JT, Pintoffl JP, Al-Batran SE, Quietzsch D, Meisinger I, Horger M, et al. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multi-center phase II study. Onkologie. 2007;30:235-40. (Pubitemid 46674905)
34. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27:2667-71. (Pubitemid 47227980)
35. Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol. 2008;19:1135-40. (Pubitemid 351796339)
36. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol. 2008;61:631-7.
37. Park SH, Kim YS, Hong J, Park J, Nam E, Cho EK, et al. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drugs. 2008;19:303-7.
38. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, et al. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61:157-65. (Pubitemid 47512637)
39. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008;63:1-8.
40. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/ doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol. 2008;38:176-81. (Pubitemid 351419740)
41. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19:1013-8.
42. Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli-Bosc FX. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol. 2009;64:549-55.
43. Leary A, Assersohn L, Cunningham D, Norman AR, Chong G, Brown G, et al. A phase II trial evaluating capecitabine and iri-notecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2009;64:455-62.
44. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, et al. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol. 2009;64:301-6.
45. *28. Pharmacogenet Genomics. 2007;17:497-504. (Pubitemid 46905216)